Triple-negative breast cancer (TNBC) is one of the prognosis poorer molecular subtypes of breast cancer with limited conventional treatments, however, it is characterized by a strong immune microenvironmental activity, which provides a certain biological basis for immunotherapy as well as antibody-drug conjugates (ADCs). Nowadays, the combination of immune checkpoint inhibitors and chemotherapy, as well as the successive introduction of ADCs such as sacituzumab govitecan and trastuzumab deruxtecan, has changed the therapeutic pattern of TNBC and provided new ideas for the development of new drugs for TNBC. In this paper, the clinical research progress of immunotherapy and ADCs for the treatment of TNBC is reviewed, in order to provide a reference for the strategy selection of clinical drugs, that is, the future research and development trend.

1.Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.

2.Tong L, Yu X, Wang S, et al. Research progress on molecular subtyping and modern treatment of triple-negative breast cancer[J]. Breast Cancer (Dove Med Press), 2023, 15: 647-658. DOI: 10.2147/BCTT.S426121.

3.Hammond ME, Hayes DF, Dowsett M, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)[J]. Arch Pathol Lab Med, 2010, 134(7): e48-72. DOI: 10.5858/134.7.e48.

4.Hammond ME, Hayes DF, Dowsett M, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Clin Oncol, 2010, 28(16): 2784-2795. DOI: 10.1200/JCO.2009.25.6529.

5.Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update[J]. J Clin Oncol, 2013, 31(31): 3997-4013. DOI: 10.1200/JCO.2013.50.9984.

6.Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases[J]. Cancer, 2008, 113(10): 2638-2645. DOI: 10.1002/cncr.23930.

7.Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed african-American and caucasian patients: a single-institution compilation compared with the national cancer institute's surveillance, epidemiology, and end results database[J]. Cancer, 2007, 110(4): 876-884. DOI: 10.1002/cncr.22836.

8.Zhu S, Wu Y, Song B, et al. Recent advances in targeted strategies for triple-negative breast cancer[J]. J Hematol Oncol, 2023, 16(1): 100. DOI: 10.1186/s13045-023-01497-3.

9.Debien V, De Caluwé A, Wang X, et al. Immunotherapy in breast cancer: an overview of current strategies and perspectives[J]. NPJ Breast Cancer, 2023, 9(1): 7. DOI: 10.1038/s41523-023-00508-3.

10.Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer[J]. J Natl Compr Canc Netw, 2020, 18(4): 479-489. DOI: 10.6004/jnccn.2020.7554.

11.Chu Y, Zhou X, Wang X. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress[J]. J Hematol Oncol, 2021, 14(1): 88. DOI: 10.1186/s13045-021-01097-z.

12.林云, 张妍, 陈曦. 靶向Trop2的抗体偶联药物治疗三阴性乳腺癌的研究进展[J]. 中国肿瘤临床, 2023, 50(18): 946-950. [Lin Y, Zhang Y, Chen  X. Research progress of antibody-drug conjugates targeting Trop2 in the treatment of triple negative breast cancer[J]. Chinese Clinical Oncology, 2023, 50(18): 946-950.] DOI: 10.12354/j.issn.1000-8179.2023.20230488.

13.Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma[J]. N Engl J Med, 2019, 381(16): 1535-1546. DOI: 10.1056/NEJMoa1910836.

14.Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(22): 2078-2092. DOI: 10.1056/NEJMoa1801005.

15.Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study[J]. J Clin Oncol, 2016, 34(21): 2460-2467. DOI: 10.1200/jco.2015.64.8931.

16.Lu CC, Beckman RA, Li XN, et al. Tumor-agnostic approvals: insights and practical considerations[J]. Clin Cancer Res, 2024, 30(3): 480-488. DOI: 10.1158/1078-0432.Ccr-23-1340.

17.Marcus L, Lemery SJ, Keegan P, et al. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors[J]. Clin Cancer Res, 2019, 25(13): 3753-3758. DOI: 10.1158/1078-0432.CCR-18-4070.

18.Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study[J]. J Clin Oncol, 2020, 38(1): 1-10. DOI: 10.1200/JCO.19.02105.

19.Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 372(26): 2509-2520. DOI: 10.1056/NEJMoa1500596.

20.Cortes-Ciriano I, Lee S, Park WY, et al. A molecular portrait of microsatellite instability across multiple cancers[J]. Nat Commun, 2017, 8: 15180. DOI: 10.1038/ncomms15180.

21.Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types[J]. JCO Precision Oncology, 2017, 2017: PO.17.00073. DOI: 10.1200/po.17.00073.

22.张凤, 姜曼, 周娜, 等. 小细胞肺癌精准治疗进展[J]. 精准医学杂志, 2022, 37(2): 184-188. [Zhang F, Jiang M, Zhou N, et al. Progress in precision therapy for small cell lung cancer[J]. Journal of Precision Medicine, 2022, 37(2): 184-188.] DOI: 10.13362/j.jpmed.202202019.

23.Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745.

24.Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer[J]. Cancer Immunol Immunother, 2021, 70(3): 607-617. DOI: 10.1007/s00262-020-02736-z.

25.Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J]. N Engl J Med, 2018, 379(22): 2108-2121. DOI: 10.1056/NEJMoa1809615.

26.Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer[J]. Ann Oncol, 2021, 32(8): 994-1004. DOI: 10.1016/j.annonc.2021.05. 801.

27.Winer EP, Lipatov O, Im S-A, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(4): 499-511. DOI: 10.1016/S1470-2045(20)30754-3.

28.Cortés J, Lipatov O, Im SA, et al. LBA21- KEYNOTE-119: phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)[J]. Ann Oncol, 2019, 30: v859-v860. DOI: 10.1093/annonc/mdz394.010.

29.Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial[J]. Lancet, 2020, 396(10265): 1817-1828. DOI: 10.1016/S0140-6736(20)32531-9.

30.Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer[J]. N Engl J Med, 2022, 387(3): 217-226. DOI: 10.1056/NEJMoa2202809.

31.Tolaney SM, Kalinsky K, Kaklamani VG, et al. Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): a phase Ib/II study[J]. Clin Cancer Res, 2021, 27(11): 3061-3068. DOI: 10.1158/1078-0432.Ccr-20-4726.

32.Loap P, Loirat D, Berger F, et al. Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer: the phase 1 olaparib and radiation therapy for triple-negative breast cancer trial[J]. JAMA Oncol, 2022, 8(12): 1802-1808. DOI: 10.1001/jamaoncol.2022.5074.

33.Yuan Y, Egelston C, Colunga Flores O, et al. CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study[J]. Ther Adv Med Oncol, 2023, 15: 17588359231210675. DOI: 10.1177/17588359231210675.

34.Corti C, Giachetti P, Eggermont AMM, et al. Therapeutic vaccines for breast cancer: has the time finally come?[J]. Eur J Cancer, 2022, 160: 150-174. DOI: 10.1016/j.ejca. 2021.10.027.

35.Vankemmelbeke M, Durrant L. Third-generation antibody drug conjugates for cancer therapy-a balancing act[J]. Ther Deliv, 2016, 7(3): 141-144. DOI: 10.4155/tde-2016-0002.

36.Li CW, Lim SO, Chung EM, et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1[J]. Cancer Cell, 2018, 33(2): 187-201. e10. DOI: 10.1016/j.ccell.2018.01.009.

37.Barroso-Sousa R, Tolaney SM. Clinical development of new antibody-drug conjugates in breast cancer: to infinity and beyond[J]. BioDrugs, 2021, 35(2): 159-174. DOI: 10.1007/s40259-021-00472-z.

38.Morrison L, Okines A. Systemic therapy for metastatic triple negative breast cancer: current treatments and future directions[J]. Cancers (Basel), 2023, 15(15): 3801. DOI: 10.3390/cancers15153801.

39.Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications[J]. Genes Cancer, 2015, 6(3-4): 84-105. DOI: 10.18632/genesandcancer.40.

40.Zhao W, Kuai X, Zhou X, et al. Trop2 is a potential biomarker for the promotion of EMT in human breast cancer[J]. Oncol Rep, 2018, 40(2): 759-766. DOI: 10.3892/or.2018.6496.

41.Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial[J]. Ann Oncol, 2021, 32(6): 746-756. DOI: 10.1016/j.annonc.2021.03.005.

42.Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J]. N Engl J Med, 2021, 384(16): 1529-1541. DOI: 10.1056/NEJMoa2028485.

43.Diéras V, Weaver R, Tolaney SM, et al. Abstract PD13-07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer[J]. Cancer Res, 2021, 81(4_Supplement): PD13-07-PD13-07. DOI: 10.1158/1538-7445.SABCS20-PD13-07.

44.Vejjasilpa K, Nasongkla N, Manaspon C, et al. Antitumor efficacy and intratumoral distribution of SN-38 from polymeric depots in brain tumor model[J]. Exp Bio Med, 2015, 240(12): 1640-1647. DOI: 10.1177/ 1535370215590819.

45.邢钊敏. 德曲妥珠单抗（T-DXd）治疗 HER-2 低表达乳腺癌的研究进展[J]. 实用医学研究, 2023, 5(3): 10-13. [Xing ZM. Research progress of trastuzumab (T-DXd) in the treatment of HER-low expression breast cancer[J]. Journal of Practical Medical Research, 2023, 5(3): 10-13.] DOI: 10.12346/pmr.v5i3.8511.

46.Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer[J]. N Engl J Med, 2019, 382(7): 610-621. DOI: 10.1056/NEJMoa1914510.

47.Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study[J]. J Clin Oncol, 2020, 38(17): 1887-1896. DOI: 10.1200/JCO.19.02318.

48.Diéras V, Deluche E, Lusque A, et al. Abstract PD8-02: trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: a phase II study with biomarkers analysis (DAISY)[J]. Cancer Res, 2022, 82(4_Supplement): PD8-02. DOI: 10.1158/1538-7445.SABCS21-PD8-02.

49.Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20. DOI: 10.1056/NEJMoa2203690.